Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2008

View Archived Issues

New analgesic agents imparted in recent patents

Pfizer patents novel 5-HT2C receptor antagonists for sexual dysfunction

Boehringer Ingelheim offers pipeline update

Product and pipeline highlights at Gilead Sciences

FDA approves orphan drug status for new cancer drug for children

Anti-flunitrazepam monoclonal antibody prevents sedative and cognitive effects of flunitrazepam

TorreyPines initiates dosing of first cohort in phase I clinical trial of NGX-426

3M and VaxInnate sign license agreement to develop flu vaccine patch

Intercell presents update on regulatory approval processes for encephalitis vaccine Ixiaro

Bayer licenses exclusive worldwide rights to use ImmunoGen's TAP technology

Myriad Genetics to spin-off research and drug development businesses

DSMB recommends continuation of Chelsea's phase II clinical trial of CH-1504 in RA

Uluru initiates clinical study of graft donor sites treated with Altrazeal Silver

Phynova reports preclinical results and selects PYN-6 as next clinical candidate

Recent Actelion patent imparts novel immunosuppressant agents

Prostatic acid phosphatase suppresses pain in chronic pain models

Preclinical profile of anticancer agent UNBS-5162 described

Preliminary phase II data on neratinib in non-small cell lung cancer presented

Weight loss seen with phentermine/topiramate in patients with type 2 diabetes

Antigenics submits MAA to EMEA for Oncophage in renal cell carcinoma

FDA approves Prezista once-daily as part of combination therapy in HIV

LCT receives approval in New Zealand to start phase I/IIa DiabeCell study

NeurogesX submits NDA for NGX-4010 for postherpetic neuralgia

Targanta releases phase II results evaluating single or infrequent oritavancin doses

MethylGene initiates dosing in phase I MGCD-290 study

R&D highlights from the UBS Global Life Sciences Conference in New York: Merrimack Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...